Larotrectinib
Non-Hodgkin Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
372 Active assets in the Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclosporin A Memorial Sloan Kettering Cancer Center | Phase 3 | BBB |
Pegaspargase Ciusss de L'Est de l'Île de Montréal | Phase 4 | BBB |
Adriamycin National Cancer Institute (NCI) | Phase 4 | BBB |
Prednisolone Mwanasha Merrill, MD | Phase 3 | BBB |
Entecavir Fudan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Larotrectinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →